Bli medlem
Bli medlem

Du är här


EQL Pharma: EQL chooses to postpone the list change to Nasdaq Stockholm

EQL Pharma revises the schedule for the planned list change from Spotlight Stock Market to Nasdaq Stockholm's main list, with the goal that the list change will be carried out after the summer of 2021 instead of the first quarter of the financial year 2021/22 as previously communicated.

The decision to postpone the list change is due to the prioritization of the acquisition of seven product licenses in Denmark during the spring and winter, which was announced on March 15, 2021. Through that prioritization, the company needed to move resources from the listing process to the acquisition. This in combination with sick leave among key personnel has led to delays in reviewing and updating the routines required for listing on Nasdaq Stockholm's main list. The postponement of the list change does not mean a strategic change for EQL Pharma, but only that the list change takes place after the summer instead of before.

For further information, please contact:

Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.